Clinical trial
Study of Alimta and Epirubicin Administered in Patients With Locally Advanced or…
NCT00097383 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00097383 |
|---|---|
| Title | Study of Alimta and Epirubicin Administered in Patients With Locally Advanced or Metastatic Breast Cancer |
| Official title | A Phase 2 Study of Alimta and Epirubicin Administered Every 21 Days in Patients With Locally Advanced or Metastatic Breast Cancer |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | ALIMTA plus Epirubicin |
| First posted | Nov 23, 2004 |
| Last update posted | Jul 19, 2006 |
| Countries | Argentina, Belgium, Brazil, Mexico, Portugal |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: